Production of Human Liver by Intrauterine Xenotransplantation of Human Wharton???s Jelly-Derived Mesenchymal Stem Cells to Animal Fetus: A Review
Author(s): Leila Rezaeian, Seyed Ebrahim Hosseini, Mehdi Dianatpour, Mohammad Amin Edalatmanesh, Nader Tanideh, Zahra Khodabandeh, Mohamad Saeed Ahrari Khafi, Amin Tamadon
Chronic liver injury and inflammation lead to hepatic fibrosis, cirrhosis, and liver failure. Transplantation of liver is the curative therapy for end-stage liver ailment. The common problem with liver transplantation like any other organ transplantation is organ shortage. The potential role for stem cell therapy to treat liver diseases has become recently topical in medical research because of the self-renewal characteristics expressed stem cells’ differentiation potential. Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) are MSCs with multiple differentiations potential. Because of its great resources, without any damage procurement, and less immunogenicity compared with other adult MSCs, WJ-MSCs promise to be a good exogenous cell candidate for tissue engineering. We hypothesize that use of human WJ-MSCs (hWJ-MSCs) xenotransplantation to the rabbit fetus liver to produce human liver tissue in animals’ fetus.